Haemonetics Corp (NYSE: HAE)

Haemonetics Corporation is a global medical technology company dedicated to improving the quality effectiveness and efficiency of health care. The company designs develops manufactures and markets innovative medical devices and disposables that address critical needs in blood management plasma collection and hospital-based interventions. Its products are used to enhance patient outcomes and support clinical workflows across diverse healthcare settings.

Haemonetics generates revenue through the sale of its medical technologies including plasma collection devices and disposables donor management software blood collection and processing systems and hospital-focused product lines. The company serves customers worldwide through a combination of direct sales teams and independent distributors with operations spanning approximately 96 countries. Revenue is derived from recurring sales of consumables and occasional capital equipment placements.

The company operates through the following segments: Plasma Blood Center and Hospital.

• The Plasma segment includes plasma collection devices and disposables donor management software and supporting software solutions sold to plasma customers. This segment focuses on enabling efficient and safe plasma collection operations for plasma centers.

• The Blood Center segment includes blood collection and processing devices and disposables for plasma red cells and platelets. This segment supports blood centers in collecting and preparing essential blood components for transfusion medicine.

• The Hospital segment is comprised of Interventional Technologies which includes Vascular Closure Sensor-Guided Technologies and Esophageal Protection product lines and Blood Management Technologies which includes Hemostasis Management Cell Salvage and Transfusion Management product lines. This segment provides solutions aimed at improving surgical outcomes and patient safety in hospital environments.

Haemonetics holds a strong position in the medical technology industry particularly in niche markets related to blood and plasma management. The company competes with established players such as Terumo BCT Fresenius Kabi and Abbott Laboratories while differentiating itself through specialized product portfolios and a focus on clinical efficiency and blood safety. Its strategic emphasis on high-growth areas like Plasma and Hospital segments reflects its commitment to innovation and long-term value creation.

The company serves a diverse customer base including plasma collection centers blood centers hospitals and healthcare providers. Specific customer names are not disclosed in the filing but the company indicates it works with major plasma operators healthcare systems and medical institutions globally to deliver its technologies and support operational needs.